Strategy to address innovative off-label medication use in China: grading management-Reference-Cited by-同舟云学术

Strategy to address innovative off-label medication use in China: grading management

Published:2014-08-17 Issue:10 Volume:70 Page:1271-1273
ISSN:0031-6970
Container-title:European Journal of Clinical Pharmacology
language:en
Short-container-title:Eur J Clin Pharmacol

Author:

Wu Hanbin,Wu Gao

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://link.springer.com/article/10.1007/s00228-014-1729-3/fulltext.html

Reference7 articles.

1. Lenk C (2012) Off-label drug use in paediatrics: a world-wide problem. Curr Drug Targets 13(7):878–884

2. Mudur G (2004) Indian medical association wants off-label prescribing. BMJ 328(7446):974

3. Zhang Lingli LI, Youping LI, Linan Z et al (2012) Evidence-based evaluation on off-label drug use policies in 15 countries. Chin J Evid-Based Med 12(4):426–435

4. Ventola CL (2009) Off-label drug information: regulation, distribution, evaluation, and related controversies. P&T 34(8):428–440

5. Ansani N, Sirio C, Smitherman T et al (2006) Designing a strategy to promote safe, innovative off-label use of medications. Am J Med Qual 21(4):255–261

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The real-world safety of oseltamivir and baloxavir marboxil in children: a disproportionality analysis of the FDA adverse event reporting system;Frontiers in Pharmacology;2024-07-10

2. Effect of erenumab on the reversion from chronic migraine to episodic migraine in an Asian population: A post hoc analysis of the DRAGON study;Headache: The Journal of Head and Face Pain;2024-05-24

3. Off-Label Prescribing in Pediatric Population—Literature Review for 2012–2022;Pharmaceutics;2023-11-21

4. A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study;The Journal of Headache and Pain;2022-11-21

5. Management guideline for the off-label use of medicine in China (2021);Expert Review of Clinical Pharmacology;2022-09-11